Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Diabetes is defined by its association with hyperglycemia-specific microvascular complications; however, it also imparts a two- to fourfold risk of cardiovascular disease (CVD). Although microvascular complications can lead to significant morbidity and premature mortality, by far the greatest cause of death in people with diabetes is CVD. Results from randomized controlled trials have demonstrated conclusively that the risk of microvascular complications can be reduced by intensive glycemic control in patients with type 1 (1,2) and type 2 diabetes (3–5). In the Diabetes Control and Complications Trial (DCCT), there was an ∼60% reduction in development or progression of diabetic retinopathy, nephropathy, and neuropathy between the intensively treated group (goal A1C <6.05%, mean achieved A1C ∼7%) and the standard group (A1C ∼9%) over an average of 6.5 years. The relationship between glucose control (as reflected by the mean on-study A1C value) and risk of complications was log-linear and extended down to the normal A1C range (<6%) with no threshold noted. In the UK Prospective Diabetes Study (UKPDS), participants newly diagnosed with type 2 diabetes were followed for 10 years, and intensive control (median A1C 7.0%) was found to reduce the overall microvascular complication rate by 25% compared with conventional treatment (median A1C 7.9%). Here, too, secondary analyses showed a continuous relationship between the risk of microvascular complications and glycemia extending into the normal range of A1C, with no glycemic threshold. On the basis of these two large controlled trials, along with smaller studies and numerous epidemiologic reports, the consistent findings related to microvascular risk reduction with intensive glycemic control have led the American Diabetes Association (ADA) to recommend an A1C goal of <7% for most adults with diabetes (6), recognizing that more or less stringent goals may be appropriate for certain patients. Whereas many epidemiologic studies and meta-analyses …
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“However, severe hypoglycemia may also be a marker of vulnerability, without any direct causal contribution to the increased mortality (72).”
From Hypoglycemia (2018) · cites this paper as [72]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Gupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,006
Research works printed but not linked: 1
- Duckworth W, Abraira C, Moritz T, Reda D, Emannele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vikek ME, Henderson WG, Huang GD: Intensive glucose control and complications in American veterans with type 2 diabetes. N Engl J Med. In press
Cited by
Items 501–600 of 879
Achievement of therapeutic targets in Mexican patients with diabetes mellitus
Lavalle-Gonzalez, F. J., Chiquete, E., de la Luz, J., Ochoa-Guzmán, A., Sánchez-Orozco, L. V., & Godínez-Gutiérrez, S. A. (2012) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2012.07.005 · Cited by 11
Cardiovascular disease is preventable among women
Kuller, L. H. (2010) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.09.125 · Cited by 12
Chen, S., Hou, X., Sun, Y., Hu, G., Zhou, X., Xue, H., Chen, P., Wu, J., Bao, Y., & Jia, W. (2018) · Primary care diabetes · doi:10.1016/j.pcd.2017.12.005 · Cited by 13
Weng, W., Liang, Y. M., Kimball, E. S., Hobbs, T. M., & Kong, S. X. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.05.031 · Cited by 11
Shen, J. I., Nicholas, S. B., Williams, S., & Norris, K. C. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1251-4 · Cited by 10
Krum, H., McMurray, J. J. V., Horton, E. S., Gerlock, T. E., Holzhauer, B., Zuurman, L., Haffner, S. M., Bethel, M. A., Holman, R. R., & Califf, R. M. (2010) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2010.00146.x · Cited by 11
Insulin therapy for type 2 diabetes
Meneghini, L. (2012) · Endocrine · doi:10.1007/s12020-012-9817-6 · Cited by 14
¿Necesitamos nuevos tratamientos para la diabetes tipo 2?
Peralta, F. G., & Padín, C. A. (2014) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2013.10.013 · Cited by 10
Reaching HbA1cGoals with Saxagliptin in Combination with Other Oral Antidiabetic Drugs
LaSalle, J. R. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.01.2108 · Cited by 10
Update on Insulin Management in Type 2 Diabetes
Neumiller, J. J., Odegard, P. S., & Wysham, C. (2009) · Diabetes Spectrum · doi:10.2337/diaspect.22.2.85 · Cited by 13
Treatment of Type 2 Diabetes Mellitus in the Older Adult: A Review
Pratley, R. E., Heller, S. R., & Miller, M. A. (2014) · Endocrine Practice · doi:10.4158/ep13192.ra · Cited by 13
Diabetes mellitus: a complete ancient and modern historical perspective
Nwaneri, C. (2015) · Cited by 18
Do Patient Characteristics Impact Decisions by Clinicians on Hemoglobin A1c Targets?
Shahraz, S., Pittas, A. G., Lundquist, C. M., Danaei, G., & Kent, D. M. (2016) · Diabetes Care · doi:10.2337/dc16-0532 · Cited by 11
Inzucchi, S. E., & Sherwin, R. S. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1604-7.00237-2 · Cited by 10
Self-citationPark, L., & Wexler, D. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328332dfaa · Cited by 9
Breaking Barriers With Basal Insulin Biosimilars in Type 2 Diabetes
Heller, S. R., Raposo, J. F., Tofé, S., Hanif, W., Schroner, Z., Down, S., & Blevins, T. (2022) · Clinical Diabetes · doi:10.2337/cd22-0016 · Cited by 9
Abdel-Latif, M. M., Rashid, M. M., Askari, M. R., Shahidehpour, A., Ahmadasas, M., Park, M., Sharp, L. K., Quinn, L., & Çınar, A. (2024) · Signals · doi:10.3390/signals5030026 · Cited by 11
Approach to Lipid Management in the Patient With Diabetes
Kim, S. J., & Subramanian, S. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf018 · Cited by 14
Key considerations in pharmacotherapy for type 2 diabetes mellitus: a multiple target organ approach
Cornell, S. A. (2011) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2011.01302.x · Cited by 9
Mastering a mediator: blockade of CCN-2 shows early promise in human diabetic kidney disease
Twigg, S. M. (2010) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-010-0102-2 · Cited by 11
Dhanaraj, E., Raval, A. D., Yadav, R., Bhansali, A. K., & Tiwari, P. (2013) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-013-0123-5 · Cited by 14
Enninga, E. A. L., Egan, A. M., Alrahmani, L., Leontovich, A. A., Ruano, R., & Sarras, M. P. (2019) · Journal of Diabetes Research · doi:10.1155/2019/9583927 · Cited by 9
Leinwand, B., Johnsrud, M. T., Nguyen, A. P., Meyer, J. H., & Johnson, K. (2020) · Journal of Medical Economics · doi:10.1080/13696998.2020.1742131 · Cited by 9
Abdel‐Rahman, N., Calderon‐Margalit, R., Cohen, A. D., Elran, E., Golan‐Cohen, A., Krieger, M., Paltiel, O., Valinsky, L. J., Ben‐Yehuda, A., & Manor, O. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.025603 · Cited by 10
Diabetes therapy‐focus on Asia: second‐line therapy debate: insulin/secretagogues
Eldor, R., & Raz, I. (2012) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2358 · Cited by 13
Insulin plus metformin for T2DM—are there benefits?
Bailey, C. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.106 · Cited by 9
What Options Are Available When Considering Starting Insulin: Premix or Basal?
Lavernia, F. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2010.0248 · Cited by 10
Blood Glucose Control and Coronary Heart Disease
Bianchi, C., Penno, G., Miccoli, R., & Prato, S. D. (2010) · Herz · doi:10.1007/s00059-010-3340-4 · Cited by 9
Lipid Levels as Predictors of Silent Myocardial Ischemia in a Type 2 Diabetic Population in Havana
Pena, Y. T., Fernández-Britto, J. E., Bacallao, J., Batista, J. F., de León, M. L., Rodríguez, J. F., Gallestey, J. B., Cuellar, J. C. G., & Hernández, M. C. V. (2012) · MEDICC Review · doi:10.37757/mr2012v14.n1.5 · Cited by 9
The Burgeoning Public Health Impact of Diabetes
Beck, R. W. (2011) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2010.331 · Cited by 10
Glycemic Targets in Diabetes Care: Emerging Clarity after Accord.
Buse, J. B. (2015) · Europe PMC (PubMed Central) · Cited by 15
Self-citationWan, E. Y. F., Yu, E. Y. T., Fung, C. S. C., Chin, W., Fong, D., Chan, A. K. C., & Lam, C. L. K. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.01.012 · Cited by 11
Guidelines: we’ll always need them, we sometimes dislike them, and we have to make them better
Kahn, R. (2010) · Diabetologia · doi:10.1007/s00125-010-1885-7 · Cited by 9
Choudhry, N. K. (2010) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.110.957142 · Cited by 10
Subramanian, S., & Chait, A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.65798-7 · Cited by 9
Addressing Cardiovascular Risk in Patients With Type 2 Diabetes: Focus on Primary Care
STOLAR, M. W. (2010) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e3181ec04e9 · Cited by 8
Focusing on Cardiovascular Disease in Type 2 Diabetes Mellitus: An Introduction to Bromocriptine QR
Bell, D. S. H. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.09.2598 · Cited by 8
Li, X., Li, J., Guo, Y., Zhu, C., Xu, R., Li, S., Qing, P., Wu, N., Jiang, L., Xu, B., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101719 · Cited by 12
Insulin analogs for the management of type 2 diabetes
Taylor, J. R., & Campbell, K. M. (2013) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp110381 · Cited by 8
Algorithms for personalized therapy of type 2 diabetes: results of a web-based international survey
Gallo, M., Mannucci, E., Cosmo, S. D., Gentile, S., Candido, R., Micheli, A. D., Benedetto, A. D., Esposito, K., Genovese, S., Medea, G., et al. (2015) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2015-000109 · Cited by 9
Peripheral arterial disease: Evaluation, risk factor modification, and medical management
Verma, A. K., Prasad, A., Elkadi, G. H., & Chi, Y. (2011) · Journal of clinical outcomes management · Cited by 9
White, H. D., Stewart, R., Dalby, A. J., Stebbins, A., Cannon, C. P., Budaj, A., Linhart, A., Pais, P. S., Díaz, R., Steg, P. G., et al. (2020) · American Heart Journal · doi:10.1016/j.ahj.2020.04.004 · Cited by 9
Remission with an Intervention
Hanipah, Z. N., Rubino, F., & Schauer, P. R. (2023) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.09.002 · Cited by 10
Lee, M. M. Y., & Sattar, N. A. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15085 · Cited by 11
Shahreyar, M., Muppidi, V., Choudhuri, I., Sra, J. S., Tajik, A. J., & Jahangir, A. (2015) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2015.1059276 · Cited by 10
Transient ischemic attack: Part II. Risk factor modification and treatment.
Simmons, B. B., Gadegbeku, A. B., & Cirignano, B. (2012) · PubMed · Cited by 13
Aloumanis, K., Benroubi, M., Sourmeli, S., & Drossinos, V. (2013) · Primary care diabetes · doi:10.1016/j.pcd.2013.04.001 · Cited by 8
Managing Type 2 Diabetes in the Primary Care Setting: Beyond Glucocentricity
Kuritzky, L. (2010) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e3181d64344 · Cited by 9
Scott, D. (2013) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s51795 · Cited by 8
Do we need new treatments for type 2 diabetes?
Peralta, F. G., & Padín, C. A. (2014) · Endocrinología y Nutrición (English Edition) · doi:10.1016/j.endoen.2014.06.002 · Cited by 9
Physical Activity, Cardiorespiratory Fitness, and the Diabetes Spectrum
Nylén, E., & Kokkinos, P. F. (2019) · Springer eBooks · doi:10.1007/978-3-030-04816-7_11 · Cited by 9
Therapeutic Options that Provide Glycemic Control and Weight Loss for Patients with Type 2 Diabetes
Blevins, T. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.01.2111 · Cited by 8
The Oldest Gravidas: A Review of Pregnancy Risks in Women Over 45
Salmeen, K. E., & Zlatnik, M. G. (2011) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0b013e318239125b · Cited by 9
The Role of Glycemia Management in the Prevention of Cardiovascular Disease—Starting Over?
Nathan, D. M. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-12-200912150-00010 · Cited by 7
Glucose, Blood Pressure, and Cardiovascular Risk
Lleva, R. R., & Inzucchi, S. E. (2012) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.112.965046 · Cited by 8
Rydén, L., & Mellbin, L. (2017) · Circulation · doi:10.1161/circulationaha.117.027952 · Cited by 8
Association of Chronic Hyperglycemia With the Risk of Urolithiasis
Almuhanna, N. R., Alhussain, A. M., Al-Damanhouril, R. B., & Alabdullah, Q. A. (2023) · Cureus · doi:10.7759/cureus.47385 · Cited by 10
Maslat, A. O., Al-Mahmood, O. M., Khawaja, N. M., & Al‐Shdefat, R. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e23676 · Cited by 8
on behalf of the ACCADEMY Study Group, Giorda, C. B., Cercone, S., & Nada, E. (2015) · Endocrine · doi:10.1007/s12020-015-0692-9 · Cited by 8
Boye, K. S., Bae, J. P., Thieu, V. T., & Lage, M. J. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01507-0 · Cited by 8
Montesanto, A., Lagani, V., Spazzafumo, L., Tortato, E., Rosati, S., Corsonello, A., Soraci, L., Sabbatinelli, J., Cherubini, A., Conte, M., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1359482 · Cited by 8
Insulin therapy for challenging patient cases.
Shubrook, J. H. (2013) · PubMed · Cited by 7
Endovascular Versus Medical Therapy for Atherosclerotic Renovascular Disease
Yu, M. S., Folt, D. A., Drummond, C. A., Haller, S. T., Cooper, E. L., Brewster, P. S., Evans, K. L., & Cooper, C. J. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0459-4 · Cited by 9
The Kidney as a Treatment Target for Type 2 Diabetes
Dokken, B. B. (2012) · Diabetes Spectrum · doi:10.2337/diaspect.25.1.29 · Cited by 9
SHABBIR, H. F., Stein, J., Tong, D. C., Bhalla, V., & Wang, A. (2010) · Journal of Hospital Medicine · doi:10.1002/jhm.590 · Cited by 7
Antidiabetic treatment: Though lovers be lost, love shall not
Παπάνας, Ν., & Maltezos, E. (2012) · World Journal of Diabetes · doi:10.4239/wjd.v3.i9.158 · Cited by 7
Minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus
Kushner, P. R. (2010) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s10013 · Cited by 9
Testing relationships: ethical arguments for screening for type 2 diabetes mellitus with HbA1C
Degeling, C., Rock, M. J., & Rogers, W. (2011) · Journal of Medical Ethics · doi:10.1136/medethics-2011-100086 · Cited by 8
Lin, T., Wu, C., Yang, Y., Lin, L., Lin, J.-L., Chen, P., & Hwang, J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0160436 · Cited by 7
Brown, S. A., García, A. A., Orlander, P. R., & Hanis, C. L. (2017) · SAGE Open Medicine · doi:10.1177/2050312116682125 · Cited by 7
Phrommintikul, A., Krittayaphong, R., Wongcharoen, W., Boonyaratavej, S., Wongvipaporn, C., Tiyanon, W., Dinchuthai, P., Kunjara-Na-Ayudhya, R., Tatsanavivat, P., & Sritara, P. (2016) · Europe PMC (PubMed Central) · doi:10.11909/j.issn.1671-5411.2016.12.002 · Cited by 7
Advances in reducing cardiovascular risk in the management of patients with type 2 diabetes mellitus
Hu, Y. (2019) · Chronic Diseases and Translational Medicine · doi:10.1016/j.cdtm.2019.01.001 · Cited by 7
Diabetes in Long-Term Care Facilities
Singhal, A., Segal, A. R., & Munshi, M. N. (2014) · Current Diabetes Reports · doi:10.1007/s11892-013-0464-y · Cited by 7
Management of Type 2 Diabetes Mellitus
Dungan, K. M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00048-2 · Cited by 10
Varma, S., & Piatt, G. (2013) · Journal of Diabetes Mellitus · doi:10.4236/jdm.2013.34031 · Cited by 7
Managing type 2 diabetes: new policy and interventions
Gillibrand, W. P., Holdich, P., & Covill, C. (2009) · British Journal of Community Nursing · doi:10.12968/bjcn.2009.14.7.43072 · Cited by 6
Fu, H., Curtis, B. H., Schuster, D. P., Festa, A., & Kendall, D. M. (2014) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2014.0039 · Cited by 7
Iványi, T., Fövényi, J., Faludi, P., Han, J., MacConell, L., Wille, S. A., & Kiljanski, J. I. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.04.022 · Cited by 6
Moschonis, G., Karatzi, K., Apergi, K., Liatis, S., Kivelä, J., Wikström, K., Ayala‐Marín, A. M., Mateo‐Gállego, R., Tsochev, Κ., Chakarova, N. Y., et al. (2020) · Nutrients · doi:10.3390/nu12103117 · Cited by 6
Chatzis, D., Kolokathis, K., Magounaki, K., Chatzidakis, S., Avramidis, K., Leopoulou, M., Angelopoulos, T. P., & Doupis, J. (2021) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2021.17.2.92 · Cited by 8
Clinical efficacy of GLP-1 agonists and their place in the diabetes treatment algorithm.
Unger, J. (2011) · PubMed · Cited by 7
Banerji, M. A., Baron, M. A., Gao, L., & Blonde, L. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.05.2761 · Cited by 6
‘Patient-Centered Care’ for Complex Patients with Type 2 Diabetes Mellitus–-Analysis of Two Cases
Hackel, J. M. (2013) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.4137/cmed.s12231 · Cited by 7
Klobucar, T. F., Hibbs, R., Jans, P., & Adams, M. R. (2012) · Professional Case Management · doi:10.1097/ncm.0b013e31823ba3cb · Cited by 11
Residual cardiovascular risk in secondary prevention
Zambon, A. (2011) · Internal and Emergency Medicine · doi:10.1007/s11739-011-0689-1 · Cited by 8
Managing Diabetes From First Diagnosis
Kruger, D. (2012) · The diabetes educator · doi:10.1177/0145721712450619 · Cited by 3
Cavicchioli, M. G. S., Guerbali, C. C. L., Ochiai, C., da Silva, R. M., Câmara, G. B., & Petry, T. B. Z. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0591-4 · Cited by 6
Introducing Insulin into Diabetes Management: Transition Strategies for Older Adults
Spain, M. P., & Edlund, B. J. (2011) · Journal of Gerontological Nursing · doi:10.3928/00989134-20110309-01 · Cited by 6
Honey: Profile and Features: Applications to Diabetes
Erejuwa, O. O. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813822-9.00031-x · Cited by 9
Intensive Insulin Therapy (Basal-Bolus)
Chico, A. I., & Corcoy, R. (2020) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001152 · Cited by 6
Reges, O., Leibowitz, M., Hoshen, M., Leventer‐Roberts, M., Greenland, P., & Balicer, R. D. (2017) · European Journal of Preventive Cardiology · doi:10.1177/2047487317702041 · Cited by 7
Clinical implications of cardiovascular outcome trials in type 2 diabetes
Mellbin, L., Wang, A., & Rydén, L. (2019) · Herz · doi:10.1007/s00059-019-4789-4 · Cited by 6
Ware, W. R. (2010) · Cited by 6
Syed, A., Don, Z. M., Ng, C. J., Lee, Y. K., Khoo, E. M., Lee, P. Y., Abdullah, K. L., & Zainal, A. Z. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-014260 · Cited by 6
Gijo, T. (2015) · The University of Queensland · doi:10.14264/uql.2015.463 · Cited by 6
Cardiovascular Outcomes Trials in Type 2 Diabetes Mellitus
Kapoor, K., George, P., & Miller, M. J. (2016) · Cardiology · doi:10.1159/000446471 · Cited by 5
Biodistribution of Insulin Following Massive Insulin Subcutaneous Injection
Ikeda, T., Tani, N., Hirokawa, T., Ikeda, K., Morioka, F., Shida, A., Aoki, Y., & Ishikawa, T. (2022) · Internal Medicine · doi:10.2169/internalmedicine.7364-21 · Cited by 5
Non-ICU Hospital Care of Diabetes Mellitus in the Elderly Population
Gilden, J. L., & Gupta, A. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0596-3 · Cited by 7
Pharmacotherapy for obesity: a field in crisis?
Fenske, W. K., Parker, J., & Bloom, S. R. (2011) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.11.50 · Cited by 5
Optimizing Inpatient Glycemic Control with Basal-Bolus Insulin Therapy
Pollom, R. D. (2010) · Hospital Practice · doi:10.3810/hp.2010.11.346 · Cited by 5
Metadata
- Authors
- Skyler, J. S., Bergenstal, R., Bonow, R. O., Buse, J., Deedwania, P., Gale, E. A. M., Howard, B. V., Kirkman, M. S., Kosiborod, M., Reaven, P., & Sherwin, R. S.
- Affiliations
- University of Miami (US)
- Park Nicollet Clinic (US)
- Northwestern University (US)
- University of North Carolina at Chapel Hill (US)
- University of California, San Francisco (US)
- University of Bristol (GB)
- American Diabetes Association (US)
- Saint Luke's Hospital (US)
- Carl T. Hayden Veterans Affairs Medical Center (US)
- Yale University (US)
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2009-01-01
- Volume
- 32
- Issue
- 1
- Pages
- 187-192
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2606812
- OpenAlex
- W2181092548
- Cited by
- 881
- References
- 22
- Citations by year
- 2026: 6 · 2025: 12 · 2024: 13 · 2023: 24 · 2022: 23 · 2021: 32 · 2020: 37 · 2019: 40 · 2018: 43 · 2017: 46 · 2016: 53 · 2015: 70 · 2014: 56 · 2013: 68 · 2012: 101
- FWCI
- 62.17
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Amylin Pharmaceuticals
- Sanofi
- Edwards Lifesciences
- Osiris Therapeutics
- Insulet Corporation
- MannKind Corporation
- Halozyme
- Dexcom
- Tandem Diabetes Care
- Daiichi-Sankyo
- Novo Nordisk
- Pfizer Pharmaceuticals
- Daiichi Sankyo Company
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- tight glycemic control, cardiovascular events, type 1 diabetes, type 2 diabetes, microvascular complications, HbA1c targets, ACCORD trial, ADVANCE trial, Diabetes Control and Complications Trial, UKPDS, diabetic retinopathy, diabetic nephropathy, diabetic neuropathy, cardiovascular risk
- MeSH terms
- Adult, Aged, Blood Glucose, Cardiovascular Diseases, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Homeostasis, Humans, Hyperglycemia, Middle Aged, Risk Factors, Sensitivity and Specificity, Randomized Controlled Trials as Topic, Risk Assessment, Diabetes Complications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.